Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598924 | 0.92 | CHRM2 (0.30) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL6762203 | 0.92 | CHRM2 (0.30) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL22656876 | 0.87 | CHRM2 (0.30) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL573582 | 0.84 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL29742575 | 0.84 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13455585 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL25245581 | 0.81 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL21844857 | 0.81 | — | — | |
| SCHEMBL29023882 | 0.81 | — | — | |
| SCHEMBL28436926 | 0.81 | TTR (0.40) | CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072178-B1 | USE OF LITHIUM BIS(FLUOROSULFONYL) IMIDE (LIFSI) IN NON-AQUEOUS ELECTROLYTE SOLUTIONS FOR USE WITH 4.2V AND HIGHER CATHODE MATERIALS FOR LITHIUM ION BATTERIES | SHENZHEN CAPCHEM TECHNOLOGY CO LTD (CN) | 2019-04-10 | — | — | EP | claimed |
| US-9698447-B2 | Use of lithium bis(fluorosulfonyl) imide (LiFSI) in non-aqueous electrolyte solutions for use with 4.2v and higher cathode materials for lithium ion batteries | BASF CORPORATION (US) | 2017-07-04 | — | — | US | claimed |
| EP-3072178-A1 | USE OF LITHIUM BIS(FLUOROSULFONYL) IMIDE (LIFSI) IN NON-AQUEOUS ELECTROLYTE SOLUTIONS FOR USE WITH 4.2V AND HIGHER CATHODE MATERIALS FOR LITHIUM ION BATTERIES | BASF Corporation (US) | 2016-09-28 | — | — | EP | claimed |
| US-20150140446-A1 | Use Of Lithium Bis(Fluorosulfonyl) Imide (LIFSI) In Non-Aqueous Electrolyte Solutions For Use With 4.2v And Higher Cathode Materials For Lithium Ion Batteries | BASF CORPORATION (US) | 2015-05-21 | — | — | US | claimed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | claimed |
| EP-1003721-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | claimed |
| WO-1999010325-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 1999-03-04 | — | — | WO | claimed |
| CN-114573616-A | Ternary electrolyte containing bicyclic salt and preparation method and application thereof | 北京卫蓝新能源科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-110444814-B | Chargeable and dischargeable aqueous solution energy storage device | 南京工业大学 | 2021-08-24 | — | — | CN | disclosed |
| US-9637456-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160016908-A1 | 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
| US-9181181-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2015-11-10 | — | — | US | disclosed |
| EP-1003721-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999010325-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| US-5778515-A | METHOD OF PREPARING AN ELECTRODE/SEPARATOR ASSEMBLY | VALENCE TECHNOLOGY, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5145900-A | Polyoxymethylene homo- and copolymer, removing binder | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| EP-0052916-B1 | ERODIBLE POLYMER CONTAINING EROSION RATE MODIFIER | ALZA CORPORATION (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4018837-A | Stabilized methylchloroform | THE DOW CHEMICAL COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016908-A1 | 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CHRM2 2370/4885CHRM4 1925/4885CHRM5 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.